Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 52

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 52
---
9,857,143 shares issued and outstanding(1)(2) 
     986 
  
    Additional paid-in capital 
     34,014 
  
    Accumulated deficit 
     (279,845)
  
    Total Shareholders’ Deficit 
     (244,845)
  
    Total Liabilities and Shareholders’ Deficit 
    $550,824 

  (1) Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender
and forfeiture if the over-allotment option is not exercised in full by the underwriters (Note 5). In February 2025 the over-allotment
option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 9).  (2) On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor holds 9,857,143 ordinary shares (the “Founder Shares”). All share and per share data has been retrospectively presented. 

The accompanying notes are an integral part
of the financial statements.

F-3

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENT OF OPERATIONS

FOR THE PERIOD FROM MAY 23, 2024 (INCEPTION)
THROUGH DECEMBER 31, 2024

    General and administrative costs 
    $279,845 
  
    Net Loss 
    $(279,845)

    Weighted average shares outstanding, basic and diluted (1)(2) 
     8,571,429 

    Basic and diluted net loss per ordinary shares 
    $(0.03)

  (1) Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender and forfeiture if the over-allotment option is not exercised in full by the underwriters (Note 5). In February 2025 the over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 9).  (2) On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor holds 9,857,143 ordinary shares (the “Founder Shares”). All share and per share data has been retrospectively presented. 

The accompanying notes are an integral part
of the financial statements.

F-4

DRUG